Chardan Capital Downgrades Exicure to Neutral, Lowers Price Target to $0.4
Chardan Capital analyst Keay Nakae downgrades Exicure (NASDAQ:XCUR) from Buy to Neutral and lowers the price target from $2.25 to $0.4.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 17.74% to $3.65 during Thursday's after-market session. The market value of their outstanding shares is at $19.2 million.
Chardan Capital Maintains Buy on Exicure, Lowers Price Target to $2.25
Chardan Capital analyst Keay Nakae maintains Exicure (NASDAQ:XCUR) with a Buy and lowers the price target from $7 to $2.25.
Exicure Q3 EPS $(0.27) Down From $(0.10) YoY, Sales $(3.68K) Down From $2.44M YoY; Says ‘there is substantial doubt about the Company’s ability to continue as a going concern’
Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.27) per share. This is a 170 percent decrease over losses of $(0.10) per share from the same period last year. The company reported $(3.68 thousand) in sales this
80 Biggest Movers From Yesterday
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss.
53 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss.
36 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) rose 63.9% to $1.07 in pre-market trading as the company reported a narrower Q3 loss.